Epinephrine Given for Hypotension in the Endoscopy Suite
A 68-year-old man with hypertension and diabetes is undergoing screening colonoscopy under propofol sedation. He becomes hypotensive at 82/44 mmHg. The sedation nurse draws up a drug from a syringe labeled 'neo' that was prepared earlier at the anesthesia cart and gives it as a bolus. Within 60 seconds the heart rate is 146, BP 228/118 mmHg, and the monitor shows 2 mm of ST depression in lead II. Investigation reveals the syringe had been filled from a 1 mg/mL epinephrine vial sitting beside the phenylephrine vial - same box size, similar green cap, no standardized dilution, and no barcode check on the cart.
1. Manage the next ten minutes, and explain which drug choices you would make and which you would avoid.
Read the worked answer
Recognize and stop. This is a bolus of roughly 1 mg of epinephrine in an elderly vasculopath. Stop any further dosing, call for help, get the defibrillator and a 12-lead ECG, and confirm the drug by reading the vial that was used.
Hemodynamic control
- Short-acting vasodilator (nicardipine infusion or nitroprusside) to bring the afterload down without a long tail.
- Short-acting beta-blocker (esmolol 10–20 mg boluses or infusion) for the tachycardia, but only after or alongside vasodilation. Giving esmolol alone into a high-afterload state can worsen the myocardial oxygen supply-demand mismatch.
- Avoid unopposed long-acting beta blockade and avoid a large bolus of a mixed agent that leaves you unable to titrate.
End-organ assessment. Serial troponins and repeat ECGs (the ST depression may be supply-demand ischemia or may herald takotsubo/apical ballooning), chest radiograph for pulmonary edema, glucose and lactate, urine output, and neuro checks. This patient with diabetes and hypertension is exactly the person in whom a catecholamine surge causes troponin leak or arrhythmia.
Sedation. Continue adequate sedation and analgesia so the endogenous catecholamine drive does not compound the exogenous load; treat pain. Support oxygenation and be ready for the possibility of pulmonary edema.
2. Perform a systems-based analysis of how this reached the patient. Which factors are the actionable ones?
Read the worked answer
Use a systems framework, not a person. A look-alike error in a low-workload setting is almost never explained by individual carelessness; it is the predictable output of a design that permits it.
Contributing factors
- Technology and design: two vials of the same physical size, similar cap color, and a handwritten or absent label on a syringe prepared earlier; no barcode scanning at the point of administration; no standard ready-to-use phenylephrine concentration supplied by pharmacy.
- Environment: phenylephrine in 10 mg/mL vials requires dilution, so a concentrated stock vial sits unlabeled next to drugs that are used straight; shared carts between anesthesia and sedation teams; cluttered workspace during a procedure where the operator's attention is on the endoscope.
- Task and team: a nurse working outside her usual scope reaches for a syringe prepared by someone else; no independent double-check for vasoactive boluses; no read-back.
- Organization: no policy on standardized vasopressor concentrations, no culture of stopping to verify in a non-emergency situation, and staffing ratios that leave one nurse managing sedation and hemodynamics simultaneously.
- Patient factors: hypotension prompted a rapid reach for a drug, which is when verification is skipped.
Actionable vs. noise. The nurse's action is the end of the causal chain, not the cause. The durable fixes are standardized concentrations, physical separation of concentrated stock, and barcode verification. Retraining the nurse alone would leave every other nurse equally exposed.
3. Design the improvement intervention and a measurement plan, including balancing measures and how you would avoid the classic failure modes of such projects.
Read the worked answer
Intervention bundle (targeting the two strongest contributors)
- Standardize: pharmacy-supplied, ready-to-use phenylephrine 100 mcg/mL syringes; remove 10 mg/mL vials from anesthetizing locations where a diluted product is required.
- Separate and differentiate: distinct storage bins, tall-man lettering, and a specific warming-colored cap for vasopressors; concentrated stock stored in a locked, clearly marked location.
- Verify: barcode-assisted syringe labeling and scanning at administration, plus an independent double-check for any vasoactive bolus given in a non-arrest situation.
- Constraint removal: add a second nurse or a dedicated sedation provider when hemodynamic instability arises.
Measurement
- Outcome: wrong-drug administrations per 10,000 syringes prepared; harm severity.
- Process: barcode scan compliance, availability of ready-to-use phenylephrine, frequency of unlabeled syringes found on audit.
- Balancing: time from recognition of hypotension to vasopressor administration (a safety intervention that slows treatment of hypotension is a net harm), scanning override rates, staff-reported workflow burden, and pharmacy cost and waste.
- Culture: near-miss reporting volume - expect reports to rise first; that is success, not failure.
Avoiding failure modes. Run small PDSA cycles in one endoscopy suite first; publish the run chart with annotated interventions so the effect can be attributed; feed data back to the staff weekly; and explicitly plan for sustainability (a named owner, order-set integration, new-hire orientation) so gains do not decay once attention moves elsewhere.